Algert Global’s Jade Biosciences JBIO Stock Holding History

Algert Global’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-363	Closed	-$21.1K	–	1206
2024 Q2	$21.1K	Buy	+363	New	+$241K	﹤0.01%	1473

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Algert Global's JBIO Position: Q3 2024 in Review

Algert Global sold out of Jade Biosciences (JBIO) in Q3 2024, closing a stake of 363 shares — an estimated $21.1K sold.

Algert Global first reported a position in JBIO in Q2 2024 and held it in 1 quarter. The position peaked at $21.1K in Q2 2024. 72 funds tracked by Wall St. Rank hold JBIO as of Q3 2024.

Algert Global reported no remaining Jade Biosciences position as of Q3 2024 after selling out during the quarter.
Algert Global sold 363 Jade Biosciences shares in Q3 2024, an estimated $21.1K.
Algert Global first reported a position in Jade Biosciences in Q2 2024 and held it in 1 quarter.
Algert Global's Jade Biosciences position peaked at $21.1K in Q2 2024.
72 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2024.

Based on Algert Global's 13F filing for Q3 2024, filed 12 Nov 2024.